Compare Indonesia Energy Corporation Limited (INDO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Summit Therapeutics Inc — how do they compare? Indonesia Energy Corporation Limited trades at $3.01 (market cap $46.01M), while Summit Therapeutics Inc trades at $14.47 (market cap $10.48B). The key difference: Summit Therapeutics Inc is far larger — about 227.8× Indonesia Energy Corporation Limited's market cap. Which is the better fit depends on your goals.
| INDO | SMMT | |
|---|---|---|
Market Cap | $46.01M | $10.48B |
Sector | Energy | Health |
52-Week High | $6.74 | $29.32 |
52-Week Low | $2.49 | $13.05 |
Enterprise Value | $41.38M | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.99, down 1.32% today, with a bullish technical signal from moving averages and oscillators. The company shows negative profitability metrics including -253.4% net income margin but maintains 100% analyst buy ratings. Recent operational milestones include commencement of drilling at the Kruh Block, providing potential catalysts for future revenue growth.
While current financials show significant losses, analyst optimism and recent operational progress suggest turnaround potential. Key risks include execution challenges in oil exploration and sustained negative cash flow. The stock presents speculative opportunity for investors betting on successful well development and future profitability improvement.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
